Adeena Musheer, Operations Coordinator and Educational Committee Member at MedNews Week, shared on X:
“Where does PD-L1 blockade fit after definitive chemoradiotherapy in unresectable stage III NSCLC? Our meta-analysis synthesized outcomes from 861 patients, examining the efficacy and safety of durvalumab consolidation.”
Title: Durvalumab Consolidation After Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer
Authors: Adeena Musheer, Muhammad S. Mannan, Muhammad W. Khan, Ayesha Junaid, Tuba Basit, Ali S. Hafeez, Moazzam Shahzad
